Purchase this article with an account.
Pedram Hamrah, Qiang Zhang, Ying Liu, M. Reza Dana; Novel Characterization of MHC Class II–Negative Population of Resident Corneal Langerhans Cell–Type Dendritic Cells. Invest. Ophthalmol. Vis. Sci. 2002;43(3):639-646.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. The presence of antigen-presenting cells (APCs) such as Langerhans
cells (LCs), an epithelial form of dendritic cells (DCs), in corneal
tissue is critical for generation of immune responses, including graft
rejection and herpetic keratitis. The purpose of this study was to
characterize the distribution and major histocompatibility complex
(MHC) antigen expression of corneal LCs.
methods. Normal and inflamed corneas were excised from BALB/c mice, and
immunofluorescence staining for CD11c, CD11b, CD45, CD80 (B7.1), CD86
(B7.2), CD3, and MHC class II (Ia) was performed by confocal microscopy
on wholemount corneal epithelium.
results. CD11c+ MHC class II–positive LCs were found in the limbus
and corneal periphery, but not in the center of the normal cornea.
These cells were CD45 positive, exhibiting bone marrow derivation, and
CD3 and CD11b negative, confirming a DC lineage. Additionally, these
cells were CD80 and CD86 negative, reflecting an immature phenotype. In
the central and paracentral areas, however, significant numbers of
CD11c+ LCs were detected that expressed no MHC class II. It
is important to note that although the density of the LCs declined from
the limbus toward the center of the cornea, they were always present.
In the inflamed cornea, the expression of MHC class II and
costimulatory molecules CD80 and CD86 was significantly enhanced, and
present in all parts of the cornea, in contrast to the normal cornea.
conclusions. The present study demonstrates for the first time the phenotype and
distribution of MHC class II–negative LCs in the murine corneal
epithelium. In the inflamed cornea, the LCs become activated as
reflected by expression of B7 costimulatory markers. These changes in
activation markers may provide additional information for devising
novel immunomodulatory strategies.
This PDF is available to Subscribers Only